Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SNPX logo SNPX
Upturn stock ratingUpturn stock rating
SNPX logo

Synaptogenix Inc (SNPX)

Upturn stock ratingUpturn stock rating
$7.85
Last Close (24-hour delay)
Profit since last BUY191.82%
upturn advisory
Consider higher Upturn Star rating
BUY since 17 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: SNPX (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $14

1 Year Target Price $14

Analysts Price Target For last 52 week
$14Target price
Low$1.84
Current$7.85
high$7.85

Analysis of Past Performance

Type Stock
Historic Profit 108.8%
Avg. Invested days 21
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.40M USD
Price to earnings Ratio -
1Y Target Price 14
Price to earnings Ratio -
1Y Target Price 14
Volume (30-day avg) 1
Beta 1.3
52 Weeks Range 1.84 - 7.85
Updated Date 06/30/2025
52 Weeks Range 1.84 - 7.85
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -10.46

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -17.29%
Return on Equity (TTM) -83.05%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -5152977
Price to Sales(TTM) -
Enterprise Value -5152977
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 1.28
Shares Outstanding 1389820
Shares Floating 1380698
Shares Outstanding 1389820
Shares Floating 1380698
Percent Insiders 1.9
Percent Institutions 3.76

Analyst Ratings

Rating 1
Target Price 14
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Synaptogenix Inc

stock logo

Company Overview

overview logo History and Background

Synaptogenix Inc., formerly known as Transition Therapeutics Inc., is a biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases. The company was founded in 1998 and has undergone name changes and strategic shifts, including a focus on Alzheimer's disease.

business area logo Core Business Areas

  • Drug Development: Focuses on the development and commercialization of Bryostatin-1 for the treatment of Alzheimer's disease and other neurodegenerative conditions.

leadership logo Leadership and Structure

The leadership team includes experienced pharmaceutical executives and scientists. The company operates with a lean organizational structure, focusing on research and development and clinical trials.

Top Products and Market Share

overview logo Key Offerings

  • Bryostatin-1: Bryostatin-1 is Synaptogenix's lead drug candidate for Alzheimer's disease. Currently in clinical trials. No current market share or revenue as it's not yet approved. Key competitors: Eli Lilly (Donanemab), Biogen (Aduhelm), Eisai (Leqembi).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with significant investment in research and development for neurodegenerative diseases like Alzheimer's. Regulatory hurdles and clinical trial success are critical factors.

Positioning

Synaptogenix is positioned as a company developing a novel therapy for Alzheimer's disease, targeting a different mechanism of action than existing or near-term competitors. They are a smaller player compared to established pharmaceutical giants.

Total Addressable Market (TAM)

The Alzheimer's disease market is estimated to be worth billions of dollars annually. Synaptogenix aims to capture a portion of this market with Bryostatin-1, focusing on patients who may not respond to existing treatments. The TAM is estimated in the hundreds of Billions. They are pursuing a fraction of the total market with a novel treatment.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach with Bryostatin-1
  • Experienced leadership team
  • Focus on a large and underserved market

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • High risk associated with drug development
  • Dependence on the success of Bryostatin-1

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into other neurodegenerative diseases

Threats

  • Clinical trial failures
  • Competition from established Alzheimer's treatments
  • Regulatory hurdles and delays

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • BIIB
  • ESAI

Competitive Landscape

Synaptogenix faces intense competition from larger pharmaceutical companies with established Alzheimer's treatments. Synaptogenix is currently developing Bryostatin-1, which is in Phase II of its clinical trials and has not yet had its market share analyzed. The listed competitors, LLY, BIIB, and ESAI have already developed treatments for Alzheimer's with proven market shares.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by clinical trial progress and funding rounds.

Future Projections: Future growth depends on the successful development and commercialization of Bryostatin-1. Analyst estimates are speculative and based on clinical trial outcomes.

Recent Initiatives: Focus on advancing Bryostatin-1 through clinical trials and seeking partnerships.

Summary

Synaptogenix is a high-risk, high-reward biopharmaceutical company focused on developing Bryostatin-1 for Alzheimer's disease. Its success hinges on positive clinical trial outcomes and securing partnerships. While the company operates in a large market, it faces strong competition from established players and requires significant funding to continue its research and development efforts. Potential investors should carefully consider the risks and uncertainties associated with drug development.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Industry Reports
  • Analyst Estimates

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Investments in biopharmaceutical companies are speculative and involve significant risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Synaptogenix Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2020-12-08
CEO & Director Dr. Alan J. Tuchman M.D., MBA(FAAN)
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Synaptogenix, Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. The company was incorporated in 2012 and is headquartered in New York, New York.